Maxim Group Thinks ContraVir Pharmaceuticals Inc’s Stock is Going to Recover

By Ryan Adsit

Maxim Group analyst Jason Kolbert assigned a Buy rating to ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) today and set a price target of $4. The company’s shares opened today at $0.56, close to its 52-week low of $0.45.

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -8.0% and a 33.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Arbutus Biopharma Corporation, and ImmunoCellular Therapeutics.

ContraVir Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $4.

Based on ContraVir Pharmaceuticals Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and quarterly net profit of $2.05 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $4.82 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF.